FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193431922> ?p ?o ?g. }

• W3193431922 endingPage "1138" @default.
• W3193431922 startingPage "1130" @default.
• W3193431922 abstract "Addition of a brachytherapy boost to external beam radiation therapy (EBRT) reduces prostate cancer (PCa) recurrence at the expense of genitourinary (GU) toxicity. Whether brachytherapy boost technique, specifically low-dose-rate (LDR-BT) versus high-dose-rate (HDR-BT), impacts treatment-related toxicity is unclear.Between 2012-2018, 106 men with intermediate/high risk PCa underwent EBRT (37.5-45 Gy in 1.8-2.5 Gy/fraction) plus brachytherapy boost, either with LDR-BT (110 Gy I-125 or 100 Gy Pd-103; n = 51) or HDR-BT (15 Gy x1 Ir-192; n = 55). Patient-reported outcomes (PRO) were assessed by International Prostate Symptom Score (IPSS) and Expanded Prostate Cancer Index Composite (EPIC-CP) surveys at 3-6-month intervals for up to three years following treatment, with higher scores indicating more severe toxicity. Provider-reported GU and gastrointestinal (GI) toxicity was graded per CTCAE v5.0 at each follow-up. Linear mixed models comparing PROs between LDR-BT versus HDR-BT were fitted. Stepwise multivariable analysis (MVA) was performed to account for age, gland size, androgen deprivation therapy use, and alpha-blocker medication use. Incidence rates of grade 2+ GU/GI toxicity was compared using Fisher's exact test.Use of LDR-BT was associated with greater change in IPSS (p=0.003) and EPIC-CP urinary irritative score (p = 0.002) compared with HDR-BT, but effect size diminished over time (LDR-BT versus HDR-BT: baseline to 6-/24-month mean IPSS change, +6.4/+1.4 versus +2.7/-3.0, respectively; mean EPIC-CP irritative/obstructive change, +2.5/+0.1 versus +0.9/+0.1, respectively). Results remained significant on MVA. Post-treatment grade 2+ GU toxicity was significantly higher in the LDR-BT group (67.5% versus 42.9% for LDR-BT and HDR-BT, respectively; p <0.001). There were no differences between groups in incontinence, bowel function, and erectile function, or grade 2+ GI toxicity.Compared with LDR-BT, HDR-BT was associated with lower acute patient- and provider-reported GU toxicity." @default.
• W3193431922 created "2021-08-30" @default.
• W3193431922 creator A5008405410 @default.
• W3193431922 creator A5008502473 @default.
• W3193431922 creator A5013571534 @default.
• W3193431922 creator A5024852113 @default.
• W3193431922 creator A5029766244 @default.
• W3193431922 creator A5032305403 @default.
• W3193431922 creator A5053195367 @default.
• W3193431922 creator A5061066145 @default.
• W3193431922 creator A5065894850 @default.
• W3193431922 creator A5081519486 @default.
• W3193431922 creator A5084008644 @default.
• W3193431922 creator A5089262994 @default.
• W3193431922 creator A5091864320 @default.
• W3193431922 date "2021-11-01" @default.
• W3193431922 modified "2023-09-27" @default.
• W3193431922 title "Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer" @default.
• W3193431922 cites W1097522617 @default.
• W3193431922 cites W153693224 @default.
• W3193431922 cites W1816753630 @default.
• W3193431922 cites W1977733462 @default.
• W3193431922 cites W1983974009 @default.
• W3193431922 cites W1988275108 @default.
• W3193431922 cites W2002440908 @default.
• W3193431922 cites W2004080098 @default.
• W3193431922 cites W2041203398 @default.
• W3193431922 cites W2054899405 @default.
• W3193431922 cites W2062313368 @default.
• W3193431922 cites W2122160420 @default.
• W3193431922 cites W2124537997 @default.
• W3193431922 cites W2125843529 @default.
• W3193431922 cites W2130018416 @default.
• W3193431922 cites W2171666465 @default.
• W3193431922 cites W2417818458 @default.
• W3193431922 cites W2553678345 @default.
• W3193431922 cites W2560720608 @default.
• W3193431922 cites W2569728867 @default.
• W3193431922 cites W2617324199 @default.
• W3193431922 cites W2752992482 @default.
• W3193431922 cites W2768699815 @default.
• W3193431922 cites W2791655860 @default.
• W3193431922 cites W2809343783 @default.
• W3193431922 cites W2892887037 @default.
• W3193431922 cites W2952048364 @default.
• W3193431922 cites W2973514824 @default.
• W3193431922 cites W2980491069 @default.
• W3193431922 cites W2993539218 @default.
• W3193431922 cites W3008898652 @default.
• W3193431922 cites W3091377290 @default.
• W3193431922 cites W4233380544 @default.
• W3193431922 cites W4234812942 @default.
• W3193431922 doi "https://doi.org/10.1016/j.brachy.2021.07.005" @default.
• W3193431922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34417136" @default.
• W3193431922 hasPublicationYear "2021" @default.
• W3193431922 type Work @default.
• W3193431922 sameAs 3193431922 @default.
• W3193431922 citedByCount "4" @default.
• W3193431922 countsByYear W31934319222022 @default.
• W3193431922 countsByYear W31934319222023 @default.
• W3193431922 crossrefType "journal-article" @default.
• W3193431922 hasAuthorship W3193431922A5008405410 @default.
• W3193431922 hasAuthorship W3193431922A5008502473 @default.
• W3193431922 hasAuthorship W3193431922A5013571534 @default.
• W3193431922 hasAuthorship W3193431922A5024852113 @default.
• W3193431922 hasAuthorship W3193431922A5029766244 @default.
• W3193431922 hasAuthorship W3193431922A5032305403 @default.
• W3193431922 hasAuthorship W3193431922A5053195367 @default.
• W3193431922 hasAuthorship W3193431922A5061066145 @default.
• W3193431922 hasAuthorship W3193431922A5065894850 @default.
• W3193431922 hasAuthorship W3193431922A5081519486 @default.
• W3193431922 hasAuthorship W3193431922A5084008644 @default.
• W3193431922 hasAuthorship W3193431922A5089262994 @default.
• W3193431922 hasAuthorship W3193431922A5091864320 @default.
• W3193431922 hasConcept C121608353 @default.
• W3193431922 hasConcept C126322002 @default.
• W3193431922 hasConcept C126894567 @default.
• W3193431922 hasConcept C133507102 @default.
• W3193431922 hasConcept C207103383 @default.
• W3193431922 hasConcept C2775908122 @default.
• W3193431922 hasConcept C2776235491 @default.
• W3193431922 hasConcept C2777416452 @default.
• W3193431922 hasConcept C2777899217 @default.
• W3193431922 hasConcept C2780192828 @default.
• W3193431922 hasConcept C29730261 @default.
• W3193431922 hasConcept C2989005 @default.
• W3193431922 hasConcept C44249647 @default.
• W3193431922 hasConcept C509974204 @default.
• W3193431922 hasConcept C71924100 @default.
• W3193431922 hasConceptScore W3193431922C121608353 @default.
• W3193431922 hasConceptScore W3193431922C126322002 @default.
• W3193431922 hasConceptScore W3193431922C126894567 @default.
• W3193431922 hasConceptScore W3193431922C133507102 @default.
• W3193431922 hasConceptScore W3193431922C207103383 @default.
• W3193431922 hasConceptScore W3193431922C2775908122 @default.
• W3193431922 hasConceptScore W3193431922C2776235491 @default.
• W3193431922 hasConceptScore W3193431922C2777416452 @default.
• W3193431922 hasConceptScore W3193431922C2777899217 @default.

• next